Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 255 results for "Byetta"

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
PRWeb

Byetta Lawsuits Move Forward, With New Ruling Issued in Federa...

Byetta lawsuits(http://www.byettalawsuit.com) and other product liability claims that allege incretin mimetic Type 2 diabetes medications caused patients to develop pancreatic cancer continue to move forward in U.S. courts, Bernstein Liebhard LLP ... Digital Journal, 1 week ago
[x]  

4 images for Byetta

PRWeb, 2 weeks ago
Scottrade, 3 months ago
PR Newswire, 3 months ago
Virtual Strategy Magazine, 4 months ago

Human medicines European public assessment report (EPAR): Byetta, exenatide, Revision: 14, Authorised

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 month ago

AZs Byetta on par with Lillys Humalog in sugar control

Adding AstraZeneca's Byetta (exenatide) to basal insulin glargine/meformin is just as effective at lowering blood sugar in adults with type II diabetes as adding bolus insulin
 Big News Network6 days ago Diabetes drug exenatide as effective as bolus insulin in new study results  GM Journal1 week ago AstraZeneca's Byetta meets primary endpoint in diabetes trial and reduces weight  Pharma Letter1 week ago

Ritter Pharmaceuticals, Inc. Names Chief Executive Officer

- Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company focused on gastrointestinal disorders, announced today that Michael D. Step has been named chief executive officer, effective October 1, 2014. Mr. Step was appointed to the ...
 BioSpace1 day ago Ritter Pharmaceuticals Names Michael D. Step Chief Executive Officer  RCL Advisors1 day ago Ritter Pharmaceuticals : Names Michael D. Step Chief Executive Officer  4 Traders1 day ago
[x]  
Jutia Group

Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential

[Business Wire] Bristol-Myers Squibb Company today announced it will settle $1.4 billion in pension obligations through the purchase of a group annuity contract from The Prudential Insurance Company of America for approximately 8,000 U.S. Read ...
 Jutia Group22 hours ago Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma  Jutia Group4 days ago Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014  Jutia Group1 month ago Bristol-Myers Squibb Company (NYSE:BMY) | Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies  Jutia Group1 month ago

Weekly Diabetes Drugs: FAQs

Latest Diabetes News By Kathleen Doheny WebMD Health News Reviewed by Michael W. Smith, MD Sept. 26, 2014 -- The recent FDA approval of Trulicity (dulaglutide), an injectable type 2 diabetes drug, gives people a third option when it ...
 MedicineNet.com1 day ago

Transition Therapeutics' (TTHI) CEO Tony Cruz on Q4 2014 Results - Earnings Call Transcript

Operator Welcome to the conference call to discuss Transition Therapeutics' full year fiscal 2014 financial results. I would like to begin by reviewing the Safe Harbor provision. Certain statements made during this conference call about the ...
 Seeking Alpha5 days ago
Tamar Securities

2 Reasons Why Eli Lilly's New Diabetes Drug Might Not Become A Blockbuster

Summary Eli Lilly's once-a-week GLP-1 agonist has been approved by the FDA. The drug has been found to be non-inferior to Victoza, which dominates the GLP-1 market. Although Eli Lilly's drug is promising, a crowded market and safety concerns will ...
 Seeking Alpha6 days ago Eli Lilly receives FDA approval for treatment option of type 2 diabetes  Individual.com1 week ago Eli Lilly's Trulicity receives US FDA approval to treat adults with type 2 diabetes  PharmaBiz1 week ago Eli Lilly's Trulicity Approved by FDA for Type II Diabetes  Yahoo! Finance1 week ago
[x]  

AstraZeneca Posts Positive Data on its Type II Diabetes Drug

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight ...
 Yahoo! Finance1 week ago

AstraZeneca Posts Positive Results For Exenatide In T2D Trial

By Estel Grace Masangkay U.K. pharma giant AstraZeneca reported positive results from the Phase 3 trial of exenatide once-weekly suspension for autoinjection for patients with Type 2 diabetes. The 28 week, open label, randomized, Phase 3 ...
 Bioresearch Online1 week ago AstraZeneca reports positive results from Phase III trial of exenatide in type 2 diabetes  Pharmaceutical Business Review1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less